Ipsen – Half year statement – 2024 12 31
Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF
Boulogne-Billancourt (France), January 7th, 2025 – Under the liquidity agreement entrusted by IPSEN SA to NATIXIS ODDO BHF, as of December 31, 2024, the following resources were included to the dedicated liquidity account:
- 24,701 shares
- €2,635,980.25
It is reminded that as of the date of the implementation of the agreement, the following resources were allocated to the liquidity account:
- 12,751 shares
- €3,137,934.80
Between July 1st, 2024 and December 31st, 2024 have been executed:
- 2,936 purchase transactions
- 2,346 sell transactions
Under the same period, the volumes traded represented:
- 311,792 shares and €33,997,824.80 to the purchase
- 321,682 shares and €35,215,771.10 to the sel
Attachment
Ipsen S.A. publishes its 2025 Consolidated Financial Statements
Ipsen – January 2026 – Monthly information relative to the total number of voting rights and shares composing the share capital
Ipsen nominates Peter Guenter to its Board of Directors
Arbitration tribunal upholds Ipsen’s termination of R&D agreement with Galderma
Ipsen – December 2025 – Monthly information relative to the total number of voting rights and shares composing the share capital
Ipsen – Half year statement – 2025 12 31
Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP)
Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline
IPSEN – Buy-back programme – Art 5 of MAR – Week 49- 2025
Ipsen – November 2025 – Monthly information relative to the total number of voting rights and shares composing the share capital